KIT and gastrointestinal stromal tumor: The 2-methylpyridine compound 105g had a two- to four-fold decrease in potency against c-KIT, FLT3, and MOLM-13 cells compared with 105a, but retained activity (GI50 = 7.7 nM) against GIST-T1 cells.